منابع مشابه
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.
The brief history of pharmacogenetics has been marked by a high level of public as well as professional interest, reflecting in many respects the great promise offered by genomic approaches to biology, clinical medicine, and pharmacology over the past ∼15 years. This early interest in person-alized medicine was fueled by reviews [1, 2] in which it was predicted that drug prescribing could be un...
متن کاملAcute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
The fixed-dose combination of Efavirenz/Emtricitabine/Tenofovir is a first-line agent for the treatment of HIV; however few cases have reported hepatotoxicity associated with the drug. We report a case of Efavirenz/Emtricitabine/Tenofovir-associated hepatotoxicity presenting mainly with hepatocellular injury characterized by extremely elevated aminotransferase levels, which resolved without acu...
متن کامل[Retinal toxicity following chloroquine therapy].
CASE REPORT Two cases of bilateral ocular toxicity following chloroquine therapy in two women with systemic lupus erythematosus are presented. DISCUSSION Retinal toxicity due to chloroquine is an uncommon iatrogenic disease. It is dose-dependent. New cases are still being described despite the application of ophthalmic screening techniques.
متن کاملRetinal and ocular toxicity in ocular application of drugs and chemicals--part II: retinal toxicity of current and new drugs.
AIMS Retinal pharmacotherapy has gained great importance for the treatment of various retinal diseases. An increasing number of drugs have been constantly released into the market, especially for wet age-related macular disease and diabetic macular edema. In this review, the issues concerning the toxicity of current and new classes of drugs are discussed. METHODS An extensive search of the li...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Eye
سال: 2002
ISSN: 0950-222X,1476-5454
DOI: 10.1038/sj.eye.6700038